Lakefront Biotherapeutics (LKFT) Income from Continuing Operations (2014 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Income from Continuing Operations of 16420878.49 for Q1 2026, up 109.87% year-over-year from 7824346.09 in Q1 2025, and down 98.28% quarter-over-quarter from 955753060.31 in Q4 2025.
Powered by 
Analysis
Lakefront Biotherapeutics (LKFT) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Income from Continuing Operations for 13 consecutive years, with 16420878.49 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 109.87% year-over-year to 16420878.49; the TTM figure through Mar 2026 stood at 564830343.59 (up 385.68% YoY), while the FY2025 annual figure was 371902590.6, up 27247.38% from the prior year.
- Income from Continuing Operations declined to 16420878.49 in Q1 2026 per LKFT's latest filing, from 955753060.31 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 955753060.31 in Q4 2025 and bottomed at 587434985.69 in Q3 2025.
- Historically, Income from Continuing Operations has averaged 7130850.46 across 5 years, with a median of 12413198.14 in 2023.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 2066.43% — and 2024, when it jumped 7933.03%.
- Lakefront Biotherapeutics' Income from Continuing Operations stood at 68453496.97 in 2022, then soared by 36.11% to 43736957.3 in 2023, then soared by 146.74% to 20443298.6 in 2024, then jumped by 4575.14% to 955753060.31 in 2025, then tumbled by 98.28% to 16420878.49 in 2026.
- Business Quant data shows LKFT's Income from Continuing Operations at 16420878.49 in Q1 2026, 955753060.31 in Q4 2025, and 587434985.69 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Lakefront Biotherapeutics | 1.89 Bn | 1.89 Bn | 3.51 Mn | -50.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -50.41 Mn |
| Mar 31, 2026 | 16.42 Mn |
| Dec 31, 2025 | 329.14 Bn |
| Sep 30, 2025 | -584.83 Mn |
| Jun 30, 2025 | 177.56 Mn |
| Mar 31, 2025 | -166.39 Mn |
| Dec 31, 2024 | -3.27 Bn |
| Sep 30, 2024 | -104.40 Mn |
| Jun 30, 2024 | 52.63 Mn |
| Mar 31, 2024 | 24.30 Mn |
| Dec 31, 2023 | 6.00 Bn |
| Sep 30, 2023 | -16.07 Mn |
| Jun 30, 2023 | -671,866.35 |
| Mar 31, 2023 | -12.41 Mn |
| Dec 31, 2022 | -71.70 Bn |
| Sep 30, 2022 | -37.13 Mn |
| Jun 30, 2022 | -80.65 Mn |
| Mar 31, 2022 | -11.07 Mn |
| Dec 31, 2021 | 6.66 Mn |
| Sep 30, 2021 | -207.55 Mn |